Product Description
Selpercatinib (formerly known as LOXO-292) is a novel, ATP-competitive, highly selective, small-molecule RET kinase inhibitor.
Mechanisms of Action: RET Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Bangladesh | Belgium | Canada | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Israel | Italy | Japan | Korea | Latvia | Lithuania | Netherlands | Norway | Poland | Portugal | Romania | Russia | Saudi Arabia | Slovakia | Spain | Sweden | Switzerland | Taiwan | United Arab Emirates | United Kingdom | United States
Approved Indications: Lung Cancer | Non-Small-Cell Lung Cancer | Oncology Solid Tumor Unspecified | Small Cell Lung Cancer | Thyroid Cancer | Oncology Unspecified
Known Adverse Events: Hypertension | Mouth Abnormalities | Constipation | Diarrhea | Edema
Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, Denmark, France, Germany, Greece, Hong Kong, India, Israel, Italy, Japan, Korea, Mexico, Netherlands, Norway, Poland, Puerto Rico, Romania, Russia, Singapore, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States, Unknown Location
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Medullary Carcinoma|Neuroendocrine Carcinoma|Non-Small-Cell Lung Cancer|Small Cell Lung Cancer|Thyroid Cancer
Phase 2: Abnormalities, Multiple|Brain Stem Cancer|Central Nervous System Cancer|Colonic Diseases|Colorectal Cancer|Fibrosarcoma|Follicular Adenocarcinoma|Hodgkin Lymphoma|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Multiple Myeloma|Myofibromatosis|Oncology Solid Tumor Unspecified|Oncology Unspecified|Papillary Adenocarcinoma|Papillary Carcinoma|Papillary Follicular Carcinoma|Soft Tissue Cancer|Vision, Low
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| LIBRETTO-432 | P3 |
Active, not recruiting |
Non-Small-Cell Lung Cancer|Small Cell Lung Cancer |
2033-03-22 |
|
| J2G-MC-JZJX | P3 |
Unknown Status |
Small Cell Lung Cancer|Non-Small-Cell Lung Cancer |
2032-08-14 |
|
| RAISE | P2 |
Recruiting |
Thyroid Cancer |
2030-11-01 |
|
| LOXO-RET-17001 | P2 |
Unknown Status |
Thyroid Cancer |
2028-05-31 |